SpartaLabs
0
SpartaLabs Research · June 17, 2026

Retatrutide: Discovery and Regulatory History

A research-library account of retatrutide's (LY3437943) discovery period, scientific lineage across three receptor systems, clinical development milestones, and current investigational status. Educational reference.

retatrutideglp-1gipglucagontriple-agonistincretin-history

Introduction

Retatrutide (LY3437943) is an investigational synthetic peptide developed by Eli Lilly and Company, classified pharmacologically as a simultaneous agonist at the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). Its scientific lineage spans more than five decades of research across three distinct endocrine systems. This article traces that lineage — from the foundational discovery work on each of the three target hormones through to the clinical development milestones that define retatrutide's current position in the investigational drug pipeline.

Discovery Period: Scientific Lineage Across Three Receptor Systems

Glucagon

Glucagon was the first of retatrutide's three target hormones to be isolated. Staub, Sinn, and Behrens reported the isolation of crystalline glucagon from pancreatic extracts in 1955, characterizing it as a hyperglycemic factor distinct from insulin [1]. Glucagon's role in hepatic glucose regulation through glycogenolysis and gluconeogenesis was characterized over the subsequent decades. The cloning of the human glucagon receptor in the early 1990s provided the molecular framework for pharmacological investigation of this target and ultimately informed the design of GCGR-targeting components in multi-receptor agonists.

GIP

Glucose-dependent insulinotropic polypeptide was isolated and characterized as an incretin hormone in the early 1970s through work by Brown and colleagues at the University of British Columbia. The identification of GIP as a peptide secreted by K cells of the duodenum and jejunum in response to fat and carbohydrate ingestion, and its characterization as an insulin secretagogue under hyperglycemic conditions, established it as the first incretin hormone defined at the molecular level. The human GIPR was subsequently cloned and characterized, enabling receptor pharmacology studies that informed the design of GIPR-targeting therapeutics including retatrutide.

GLP-1

The characterization of glucagon-like peptide-1 as a biologically active incretin followed the cloning of the proglucagon gene in the early 1980s. Research groups led by Joel Habener at Massachusetts General Hospital and Svetlana Mojsov, as well as independent work by Daniel Drucker at the University of Toronto and Jens Juul Holst in Copenhagen, established that proglucagon's post-translational processing in intestinal L cells yields GLP-1, a potent glucose-dependent stimulator of insulin secretion. The subsequent discovery that exendin-4 — a peptide isolated from the Gila monster (Heloderma suspectum) by John Eng in the early 1990s — was a potent, long-acting GLP-1R agonist provided pharmacological proof-of-concept for GLP-1-based therapeutics and set the stage for the class of acylated peptide incretin agents that includes retatrutide.

Early Research: From Single-Receptor to Multi-Receptor Agonism

The first approved GLP-1 receptor agonist, exenatide (synthetic exendin-4), received FDA approval in 2005 under the brand name Byetta. Subsequent GLP-1R agonists with extended half-lives — including liraglutide (2010), dulaglutide (2014), and semaglutide (2017) — followed, each employing fatty acid acylation or albumin-fusion strategies to extend the molecule's plasma half-life relative to native GLP-1's sub-two-minute biological half-life.

The hypothesis that multi-receptor engagement within the incretin system might produce metabolic effects beyond those achievable by selective GLP-1R agonism drove a parallel research program during the 2010s. Academic and industry investigators published preclinical data examining the effects of dual or triple receptor co-agonism using peptide chimeras designed to engage two or three of the GLP-1R, GIPR, and GCGR simultaneously.

At Eli Lilly and Company, this scientific program produced tirzepatide (LY3298176), a dual GIPR/GLP-1R agonist first described in the peer-reviewed literature by Coskun and colleagues in 2018. The clinical development of tirzepatide through the SURPASS and SURMOUNT trial programs, and its FDA approval in 2022 (Mounjaro) and 2023 (Zepbound), provided clinical proof-of-concept for multi-receptor incretin agonism and informed the scientific rationale for advancing a triple receptor agonist. The same Lilly research program advanced work on incorporating glucagon receptor agonism into the dual incretin scaffold, resulting in LY3437943 (retatrutide), on the basis that glucagon signaling in multiple tissues might contribute an additional pharmacological dimension to the dual incretin effects.

Regulatory Milestones

Phase 1 — 2022

The first peer-reviewed publication of multi-dose human clinical data for LY3437943 appeared in The Lancet in November 2022. Urva, Coskun, and colleagues reported results from a phase 1b, multicenter, double-blind, placebo-controlled, randomized, multiple-ascending-dose trial in adults with type 2 diabetes [2]. The trial characterized the compound's pharmacokinetic profile as supporting once-weekly administration and provided initial safety and pharmacodynamic data in humans. This publication constituted the compound's formal entry into the peer-reviewed clinical literature.

Phase 2 — 2023–2024

Two phase 2 clinical trial reports for retatrutide appeared in major journals in 2023, substantially advancing the compound's published clinical data package.

Jastreboff, Kaplan, Frías, and colleagues reported results from a 48-week phase 2, double-blind, randomized, placebo-controlled trial in adults with obesity or overweight in the New England Journal of Medicine on June 26, 2023 [3]. The publication attracted broad attention in the cardiometabolic research community. The trial was registered as NCT04881760.

In the same year, Rosenstock, Frías, Jastreboff, and colleagues reported results from a 36-week phase 2, randomized, double-blind, placebo and active-controlled trial in adults with type 2 diabetes in The Lancet [4], with dulaglutide as an active comparator.

A phase 2a investigation in metabolic dysfunction-associated steatotic liver disease (MASLD), conducted by Sanyal, Kaplan, Frías, Brouwers, and colleagues, was published in Nature Medicine in 2024 [5], extending the compound's published research profile to a third clinical population and a distinct tissue endpoint.

A cryo-electron microscopy structural characterization of retatrutide's binding interactions at all three receptor complexes, published by Li and colleagues in Cell Discovery in 2024 [6], provided atomic-resolution molecular context for the clinical pharmacology data across this period.

Phase 3 Registrations — 2023–2024

Following the phase 2 data package, Eli Lilly registered multiple phase 3 trials for retatrutide beginning in 2023. The TRIUMPH program addressed obesity and overweight indications, with TRIUMPH-1 (NCT05929066) enrolling adults without type 2 diabetes. The TRANSCEND program addressed type 2 diabetes indications, with TRANSCEND-T2D-1 (NCT06354660) enrolling adults with type 2 diabetes and inadequate glycemic control on diet and exercise alone, and TRANSCEND-T2D-2 (NCT06260722) enrolling adults on metformin with or without SGLT2 inhibitors. Additional trials examined retatrutide in adults with obesity and osteoarthritis (NCT05931367) and chronic low back pain (NCT07035093), reflecting an expansive investigation of potential research applications.

Current Research Landscape

As of mid-2026, retatrutide's clinical development program is among the most extensive registered for any investigational triple receptor agonist. The TRANSCEND-T2D-1 phase 3 trial reported initial results in The Lancet in 2026 [7], marking the compound's first peer-reviewed pivotal trial publication. Phase 3 results from the TRIUMPH obesity program trials were expected in the near term, with enrollment complete at the time this article was prepared.

The compound's structural pharmacology literature continued to advance alongside its clinical development program. The 2024 cryo-electron microscopy study from Li and colleagues [6] characterized the molecular basis of retatrutide's triple receptor engagement at atomic resolution, a level of structural detail that informs ongoing academic pharmacology investigation.

Retatrutide remains an investigational compound without regulatory approval as of this writing. Its clinical development trajectory — from discovery publication in 2022 through phase 3 reporting in 2026 — reflects a compressed timeline consistent with the scientific priority placed on this pharmacological class. Research-grade retatrutide from SpartaLabs is available with third-party-verified purity documentation for investigational use.

References

  1. Staub A, Sinn L, Behrens OK. Purification and crystallization of glucagon. J Biol Chem. 1955;214(2):619-632. PMID: 14367373

  2. Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881. DOI: 10.1016/S0140-6736(22)02033-5

  3. Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. Triple–hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315. DOI: 10.1056/NEJMoa2301972

  4. Rosenstock J, Frías JP, Jastreboff AM, Du Y, Lou J, Gurbuz S, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. DOI: 10.1016/S0140-6736(23)01053-X

  5. Sanyal AJ, Kaplan LM, Frías JP, Brouwers B, Wu Q, Thomas MK, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(8):2037-2048. DOI: 10.1038/s41591-024-03018-2

  6. Li W, Zhou Q, Cong Z, Yuan Q, Li W, Zhao F, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discov. 2024;10:77. PMID: 39019866. DOI: 10.1038/s41421-024-00700-0

  7. The Lancet. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026. DOI: 10.1016/S0140-6736(26)00967-0

Frequently asked questions

  • When was retatrutide discovered?

    The compound designated LY3437943 was first described in the peer-reviewed literature in 2022, when Coskun, Urva, Roell, and colleagues published the molecule's design rationale, receptor binding profile, preclinical metabolic data, and phase 1 single-ascending-dose clinical findings in Cell Metabolism. Its scientific lineage, however, traces through decades of research on each of the three receptor systems it targets, with glucagon first isolated in 1955, GIP characterized in the early 1970s, and GLP-1 identified in the 1980s.

  • Who developed retatrutide?

    Retatrutide was developed by Eli Lilly and Company as an extension of their earlier tirzepatide research program. The scientific program at Lilly that produced tirzepatide — a dual GIPR/GLP-1R agonist — subsequently investigated the addition of glucagon receptor agonism to the dual incretin scaffold, resulting in LY3437943.

  • What is the regulatory history of retatrutide?

    Retatrutide entered the peer-reviewed clinical literature with a phase 1b multicenter trial reported in The Lancet in November 2022. Phase 2 trial results were published in the New England Journal of Medicine and The Lancet in 2023, followed by a phase 2a MASLD trial in Nature Medicine in 2024. Phase 3 trials were registered under the TRIUMPH and TRANSCEND programs beginning in 2023, with TRANSCEND-T2D-1 reporting initial results in The Lancet in 2026. Retatrutide has not received regulatory approval for any therapeutic indication.

  • What was the first GLP-1 receptor agonist approved by the FDA?

    The first approved GLP-1 receptor agonist was exenatide (synthetic exendin-4), which received FDA approval in 2005 under the brand name Byetta. Subsequent acylated GLP-1R agonists with extended half-lives followed, including liraglutide (2010), dulaglutide (2014), and semaglutide (2017), each employing fatty acid acylation or albumin-fusion strategies to extend plasma half-life relative to native GLP-1.